Industry Overview
Global developer of medical aesthetics devices and skincare products used by leading skincare clinics and dermatologists for the rejuvenation of skin. The Company's products stimulates the skin to produce more collagen and elastin resulting in the rejuvenation of skin.
Location
Sydney, Australia
Business Description
Global developer of medical aesthetics devices and skincare products used by leading skincare clinics and dermatologists for the rejuvenation of skin. The Company's products stimulates the skin to produce more collagen and elastin resulting in the rejuvenation of skin.
Financial Summary
The company generated sales of approximately US$22 million in FY23 and is forecast to generate EDITDAR in excess of US10 million in FY24.
Investment Rationale
The company's key products have been approved as a Class 2 product suitable for sale by US Food & Drug Administration (“FDA”) and European Union (“CE”) and its products are patented on a worldwide basis.
The company is poised for significant growth with a range of additional products due for release over the next two years.
Customer Overview
Products are sold to skincare clinics and dermotologists in over 78 countries
Transaction Information
The founder is looking for a strategic investor to assist with the continue global expansion of the business.
To enquire, you will need to complete our Investor Verification Process and sign a Buyer Consent Form.
